Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailAntifracture efficacy and safety of once-yearly Zoledronic acid 5mg in men with osteoporosis: a prospective, randomized, controlled trial
Boonen, Steven; Su, Guoqin; Incera, Elodie et al

in Osteoporosis International (2011, March), 22(Suppl.1), 112

Detailed reference viewed: 78 (1 ULg)
Full Text
Peer Reviewed
See detailAntifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster, Jean-Yves ULg

in Drugs (2011), 71(1), 65-78

Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the underlying structure of bone tissue. These changes lead to an increase in bone ... [more ▼]

Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the underlying structure of bone tissue. These changes lead to an increase in bone fragility and an increased risk for fracture, which are the clinical consequences of osteoporosis. The classical triad for consideration in osteoporosis is morbidity, mortality and cost. Vertebral fracture is an important source of morbidity in terms of pain and spinal deformity. On the other hand, hip fracture is associated with the worst outcomes and is widely regarded as a life-threatening event in the elderly; it is the source of the bulk of the cost of the disease in contemporary healthcare. The prevention of osteoporosis-associated fracture should include fall prevention, calcium supplementation and lifestyle advice, as well as pharmacological therapy using agents with proven antifracture efficacy. The most commonly used osteoporosis treatments in Europe are the bisphosphonates alendronate, risedronate, ibandronate and zoledronic acid; the selective estrogen receptor modulator (SERM) raloxifene; teriparatide; and strontium ranelate. Recent additions include the biological therapy denosumab and the SERM bazedoxifene. In this review, we explore the antifracture efficacy of these agents with the aim of simplifying treatment decisions. These treatments can be broadly divided according to their mode of action. The antiresorptive agents include the bisphosphonates, the SERMs and denosumab, while the bone-forming agents include parathyroid hormone and teriparatide. Strontium ranelate appears to combine both antiresorptive and anabolic activities. We collated data on vertebral and hip fracture efficacy from the pivotal 3-year phase III trials, all of which had a randomized, double-blind, placebo-controlled design. The relative reductions in risk in the osteoporosis trials range from 30% to 70% for vertebral fracture and 30% to 51% for hip fracture. This translates into 3-year number needed to treat values of between 9 and 21 for vertebral fracture and from 48 upwards for hip fracture. International guidelines agree that agents that have been shown to decrease vertebral, nonvertebral and hip fractures should be used preferentially over agents that only demonstrate vertebral antifracture efficacy. This is the case for alendronate, risedronate, zoledronic acid, denosumab and strontium ranelate. Finally, therapeutic decisions should be based on a balance between benefits and risks of treatment, which must be carefully considered in each particular case both by the physician and the patient. Indeed, no single agent is appropriate for all patients and, therefore, treatment decisions should be made on an individual basis, taking into account all measures of treatment effect and risk before making informed judgments about the best individual treatment option. [less ▲]

Detailed reference viewed: 64 (4 ULg)
Full Text
Peer Reviewed
See detailThe antifracture efficacy of ibandronate: a compendium of evidence.
Reginster, Jean-Yves ULg

in Osteoporosis International (2009, March), 20(Suppl.1), 182-183

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailAntifungal activity of 2 lactic acid bacteria of the Weissella genus isolated from food
Ndagano, Dora; Lamoureux, Thibaut; Dortu, Carine et al

in Journal of Food Science (2011), 76(6), 305-311

Detailed reference viewed: 51 (5 ULg)
See detailAntifungal lipopeptides from B. subtilis induce defense-related phenolics in potato
Ongena, Marc ULg; Akpa, E.; Thonart, Philippe ULg et al

Poster (1999, May 04)

Detailed reference viewed: 10 (2 ULg)
See detailAntigen microencapsulation using a spray-drying technique
Zgouli, Slim; Grek, Vincent; Sabri, Ahmed ULg et al

Poster (1993, October)

Detailed reference viewed: 68 (6 ULg)
See detailAntigen microencapsulation using a spray-drying technique.
Zgoulli, S.; Gilsoul, J. J.; Gerard, J. et al

Poster (1993, October)

Detailed reference viewed: 20 (0 ULg)
Full Text
Peer Reviewed
See detailAntigen presenting cell-derived IL-6 restricts Th2-cell differentiation.
Mayer, Alice; Debuisson, Delphine; Denanglaire, Sebastien et al

in European Journal of Immunology (2014), 44(11), 3252-62

The identification of DC-derived signals orchestrating activation of Th1 and Th17 immune responses has advanced our understanding on how these inflammatory responses develop. However, whether specific ... [more ▼]

The identification of DC-derived signals orchestrating activation of Th1 and Th17 immune responses has advanced our understanding on how these inflammatory responses develop. However, whether specific signals delivered by DCs also participate in the regulation of Th2 immune responses remains largely unknown. In this study, we show that administration of antigen-loaded, IL-6-deficient DCs to naive mice induced an exacerbated Th2 response, characterized by the differentiation of GATA-3-expressing T lymphocytes secreting high levels of IL-4, IL-5, and IL-13. Coinjection of wild type and IL-6-deficient bone marrow-derived dendritic cells (BMDCs) confirmed that IL-6 exerted a dominant, negative influence on Th2-cell development. This finding was confirmed in vitro, where exogenously added IL-6 was found to limit IL-4-induced Th2-cell differentiation. iNKT cells were required for optimal Th2-cell differentiation in vivo although their activation occurred independently of IL-6 secretion by the BMDCs. Collectively, these observations identify IL-6 secretion as a major, unsuspected, mechanism whereby DCs control the magnitude of Th2 immunity. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailAntigen/antibody retention by follicular dendritic cells (FDC).
Radoux, D.; Heinen, Ernst ULg; Kinet-Denoel, C. et al

in Advances in Experimental Medicine and Biology (1985), 186

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailAntigenic and Genomic Identity between Simian Herpesvirus Aotus Type 2 and Bovine Herpesvirus Type 4
Bublot, M.; Dubuisson, J.; Van Bressem, M. F. et al

in Journal of General Virology (The) (1991), 72((Pt 3)), 715-9

Herpesvirus aotus type 2 (HVA-2) was isolated from a culture of kidney cells from a healthy owl monkey (Aotus trivirgatus). Bovine herpesvirus type 4 (BHV-4) is frequently isolated from diseased and even ... [more ▼]

Herpesvirus aotus type 2 (HVA-2) was isolated from a culture of kidney cells from a healthy owl monkey (Aotus trivirgatus). Bovine herpesvirus type 4 (BHV-4) is frequently isolated from diseased and even healthy cattle and occasionally from sheep, wild ruminants and cats. The two viruses are related antigenically, as was revealed by an indirect fluorescent antibody test using polyclonal antisera from experimentally infected rabbits or monoclonal antibodies raised against six BHV-4 proteins, three of which were glycosylated. The genome structures of the two viruses consist of a unique central sequence flanked at both ends by G + C-rich tandem repeats. Restriction maps (produced using EcoRI, BamHI and HindIII) of these two viruses were nearly identical but the unique sequence of the HVA-2 genome possessed two additional BamHI sites. Four genomic regions of variable size were detected, two located in the unique part, one in the repetitive part and one in the left junction between the unique and the repeated part of the genome; these slight variations were similar to those observed between various BHV-4 isolates. These results suggest that HVA-2 and BHV-4 belong to the same virus species; HVA-2 could be either a BHV-4 contaminant of owl monkey kidney cell cultures or an isolate from an owl monkey accidentally infected with BHV-4. [less ▲]

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailAntigenic Variants Of Bovine Leukemia-Virus (Blv) Are Defined By Amino-Acid Substitutions In The Nh2 Part Of The Envelope Glycoprotein-Gp51
Portetelle, Daniel ULg; Couez, D.; Bruck, C. et al

in Virology (1989), 169(1),

Bovine leukemia virus (BLV) p24 gene was expressed in Saccharomyces cerevisiae under the control of the PHO5 (encoding repressible acid phosphatase, rAPase) promoter. Yeast cells were transformed by a ... [more ▼]

Bovine leukemia virus (BLV) p24 gene was expressed in Saccharomyces cerevisiae under the control of the PHO5 (encoding repressible acid phosphatase, rAPase) promoter. Yeast cells were transformed by a yeast-E. coli shuttle vector carrying the PHO5 promoter, the p24 gene and the CYC1 transcription terminator. After low inorganic phosphate (Pi) induction of the PHO5 promoter, p24 accumulated in the producing cells up to a concentration representing 10% of total soluble proteins. The expression level of p24 gene was not increased by insertion of the positive regulatory gene PHO4 on the p24 expression vector. The p24 produced in this system and incubated in crude yeast extract showed a remarkably high resistance to proteolytic degradation, a feature that presumably correlates with the compact globular conformation of the protein combined to the stabilizing effect of the N-terminal residue. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailAntigens
Van Regenmortel, M; Tellam, R; Manteca, C et al

in Pastoret, PP; Blancou, J; Vannier, P (Eds.) et al Veterinary Vaccinology (1997)

Detailed reference viewed: 9 (0 ULg)
Peer Reviewed
See detailAntigens of the basement membrane and the peritumoral stroma in human colonic adenocarcinomas: an immunofluorescence study.
Burtin, P.; Chavanel, G.; Foidart, Jean-Michel ULg et al

in International Journal of Cancer = Journal International du Cancer (1982), 30(1), 13-20

Twenty colonic adenocarcinomas were studied by immunofluorescence with antisera against components of the basement membrane: type IV collagen, laminin and heparan sulfate-rich proteoglycan, as well as ... [more ▼]

Twenty colonic adenocarcinomas were studied by immunofluorescence with antisera against components of the basement membrane: type IV collagen, laminin and heparan sulfate-rich proteoglycan, as well as antisera against antigens of the connective tissue: type-III collagen, fibronectin and hyaluronectin. Marked alterations of the basement membranes were consistently observed on staining with each one of the first three antisera. In contrast, staining of the normal components of connective tissue was in most cases as intense as in normal colonic mucosa. Hyaluronectin, a marker of peritumoral stroma, was found to be present in 12 out 15 tumors studied. [less ▲]

Detailed reference viewed: 9 (0 ULg)
Full Text
See detailHet antigif. Maar is het nog op tijd?
Meesters, Gert ULg

in Over Taal (1999), 38(1), 35-36

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailAntigone et Manon s’invitent en droit social. Quelques propos sur la légalité de la preuve
Kefer, Fabienne ULg

in Revue Critique de Jurisprudence Belge (2009), 3

Detailed reference viewed: 232 (27 ULg)
See detailAntigone image de la limite: habiter le seuil du représentable chez Judith Butler
Borotto, Jessica ULg

Scientific conference (2014, December 08)

Detailed reference viewed: 18 (1 ULg)
See detailAntigone, Médée. Figures de subversion
Borotto, Jessica ULg

Conference given outside the academic context (2016)

Detailed reference viewed: 16 (0 ULg)
Peer Reviewed
See detailAntihyperglycaemic agents. Drug interactions of clinical importance.
Scheen, André ULg; Lefebvre, Pierre ULg

in Drug Safety : An International Journal of Medical Toxicology & Drug Experience (1995), 12(1), 32-45

Non-insulin-dependent (type 2) diabetes mellitus (NIDDM) affects middle-aged or elderly people who frequently have several other concomitant diseases, especially obesity, hypertension, dyslipidaemias ... [more ▼]

Non-insulin-dependent (type 2) diabetes mellitus (NIDDM) affects middle-aged or elderly people who frequently have several other concomitant diseases, especially obesity, hypertension, dyslipidaemias, coronary insufficiency, heart failure and arthropathies. Thus, polymedication is the rule in this population, and the risk of drug interactions is important, particularly in elderly patients. The present review is restricted to the interactions of other drugs with antihyperglycaemic compounds, and will not consider the mirror image, i.e. the interactions of antihyperglycaemic agents with other drugs. Oral antihyperglycaemic agents include sulphonylureas, biguanides--essentially metformin since the withdrawn of phenformin and buformin--and alpha-glucosidase inhibitors, acarbose being the only representative on the market. These drugs can be used alone or in combination to obtain better metabolic control, sometimes with insulin. Drug interactions with antihyperglycaemic agents can be divided into pharmacokinetic and pharmacodynamic interactions. Most pharmacokinetic studies concern sulphonylureas, whose action may be enhanced by numerous other drugs, thus increasing the risk of hypoglycaemia. Such an effect may result essentially from protein binding displacement, inhibition of hepatic metabolism and reduction of renal clearance. Reduction of the hypoglycaemic activity of sulphonylureas due to pharmacokinetic interactions with other drugs appears to be much less frequent. Drug interactions leading to an increase in plasma metformin concentrations, mainly by reducing the renal excretion or the hepatic metabolism of the biguanide, should be avoided to limit the risk of hyperlactaemia. Owing to its mode of action, pharmacokinetic interferences with acarbose are limited to the gastrointestinal tract, but have not been extensively studied yet. Pharmacodynamic interactions are quite numerous and may result in a potentiation of the hypoglycaemic action or, conversely, in a deterioration of blood glucose control. Such interactions may be observed whatever the type of antidiabetic treatment. They result from the intrinsic properties of the coprescribed drug on insulin secretion and action, or on a key step of carbohydrate metabolism. Finally, a combination of 2 to 3 antihyperglycaemic agents is common for treating patients with NIDDM to benefit from the synergistic effect of compounds acting on different sites of carbohydrate metabolism. Possible pharmacokinetic interactions between alpha-glucosidase inhibitors and classical antidiabetic oral agents should be better studied in the diabetic population. [less ▲]

Detailed reference viewed: 46 (0 ULg)
Full Text
Peer Reviewed
See detailAntihyperglycémiants, antihypertenseurs et hypolipidémiants : comparaison des effets sur la mortalité et la morbidité cardiovasculaire chez le patient diabétique de type 2
SCHEEN, André ULg

Poster (2016, March)

Introduction : Réduire le risque de mortalité et morbidité cardiovasculaire (CV) chez le patient diabétique de type 2 (DT2) est primordial, mais les effets protecteurs semblent différents selon le mode ... [more ▼]

Introduction : Réduire le risque de mortalité et morbidité cardiovasculaire (CV) chez le patient diabétique de type 2 (DT2) est primordial, mais les effets protecteurs semblent différents selon le mode d’intervention pharmacologique étudié. Patients et méthodes : Les données de mortalité (totale et CV) et morbidité (infarctus du myocarde ou IDM, accidents vasculaires cérébraux ou AVC) rapportées (réduction du risque relatif) dans les essais ayant testé un traitement anti-hyperglycémiant sont comparées avec les résultats publiés dans deux méta-analyses concernant les hypolipidémiants et les anti-hypertenseurs consacrées au DT2. Résultats : Les antihypertenseurs réduisent les IDM (-12%) et la mortalité globale (-13%) de façon comparable, et diminuent davantage les AVC (-27%). Les hypolipidémiants diminuent davantage les IDM (- 22%) et les AVC (-21%) que la mortalité globale (-9%) (ou la mortalité CV : - 13%). Les données concernant les antihyperglycémiants diffèrent considérablement selon les médications testées. L’insuline et les sulfamides (UKPDS) réduisent plus les IDM (- 21%) que la mortalité totale (-8%), mais augmentent les AVC (+ 14%). La metformine (UKPDS) réduit, de façon comparable, les IDM (-39%), les AVC (-41%) et la mortalité totale (-36%). La pioglitazone (PROactive) diminue davantage les IDM (-17%) et les AVC (-19%) que la mortalité (-4%). Les gliptines (combinaison de SAVOR TIMI 53, EXAMINE, TECOS) ont montré des effets globalement neutres sur la mortalité totale (0%), les IDM (-2%) et les AVC (-1%). L’empagliflozine (EMPA-REG OUTCOME) se singularise par un effet favorable nettement plus marqué sur la mortalité totale (-32 %) et CV (- 38%) que sur les IDM (-13%) ou les AVC (+18%). Conclusion : Les discordances observées suggèrent l’implication de mécanismes protecteurs différents selon les interventions testées. EMPA-REG OUTCOME, le seul essai démontrant un effet plus marqué sur la mortalité que sur les événements CV, suggère un mécanisme propre de l’inhibiteur des SGLT2. [less ▲]

Detailed reference viewed: 39 (1 ULg)
See detailAntihypertenseur et AVC - de la prévention au traitement
Krzesinski, Jean-Marie ULg

Conference (2004, March 15)

Detailed reference viewed: 48 (14 ULg)